When meta-analyzing these seven randomized controlled trials, GLP1-RAs were found to reduce major CVD events by 12% (hazard ratio [HR], 0.88; 95% CI, 0.82–0.94), CVD mortality by 12% (HR, 0.88; 95% CI, 0.81–0.96), and stroke risk by 16% (HR, 0.84; 95% CI, 0.76–0.93) [102]. The gene discussed is GLP1R; the disease is stroke disorder.